Further, MDP treatment of CLL-patient monocytes also enhanced surface expression of FcγRI and FcγRIIIa, observed by flow cytometry (Figure 4C), and expression of FcεRIγ, measured by immunoblot (Figure 4D). This evidence concerns the gene FCGR3A and B-cell chronic lymphocytic leukemia.